Evidence map›Paper›PMID 42375224›Full record

ArticleJournal of clinical and translational science2026

Prediction of α-synuclein seed amplification assay positivity in remotely followed

Ruth B Schneider, Peggy Auinger, Charles S Venuto

Abstract read
In one paragraph

Article in Journal of clinical and translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ruth B SchneiderUniversity of Rochester, Rochester, NY, USA.ORCID https://orcid.org/0000-0001-8094-4041
Peggy AuingerUniversity of Rochester, Rochester, NY, USA.
Charles S VenutoUniversity of Rochester, Rochester, NY, USA.ORCID https://orcid.org/0000-0002-2394-9513

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The α-synuclein seed amplification assay (SAA) is a biomarker for Parkinson's disease (PD) but requires cerebrospinal fluid. We applied a validated model to predict α-synuclein SAA+ using remotely collected data in LRRK2 G2019S carriers. VALOR-PD participants completed at-home olfactory and autonomic assessments. SAA+ probabilities for manifest and non-manifest carriers at baseline and month 36 visits were estimated. Baseline SAA+ mean probability was 0.57 (manifest) and 0.28 (non-manifest). Over three years, SAA+ mean probabilities increased in manifest (0.66, p = 0.014) and non-manifest carriers (0.38, p < 0.001), paralleling olfactory declines. Remotely collected data may be used to approximate SAA classification.

Indexed as

decentralized researchLRRK2Parkinson’s diseasepredictα-synuclein

Identifiers

PMID42375224
PMCPMC13312348

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.